A prospective surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan.
Not Applicable
- Conditions
- Arteriosclerosis obliterans Peripheral arterial disease
- Registration Number
- JPRN-UMIN000003385
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Brief Summary
<Journal Articles> -Int Heart J. 51(5):337-42,2010. -Circ J. 80(3):712-21,2016. -Scientific Reports 7(1):6095,2017. -Angiology Nov26,2018. -Circ J. 83(9):1029-36,2019. <Scientific Conference> -The Annual Meeting of Japanese College of Angiology 53rd (2012) 54th (2013) 55th (2014) -The Annual Scientific Meeting of the Japanse Curculation Society 77th (2013) 78th (2014) 79th (2015) -European Society of Cardiology (2015)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 11375
Inclusion Criteria
Not provided
Exclusion Criteria
The following subjects were excluded: (1)Those with contraindications to the use of targeted medication (sarpogrelate or antiplatelet agents). (2)Those considered inappropriate for the study by patient's physicians.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Combined endpoint comprised of the following cardiovascular events; - Cerebrovascular events - Cardiovascular events - Peripheral vascular events
- Secondary Outcome Measures
Name Time Method Cerebrovascular events Cardiovascular events Peripheral vascular events Total cardiovascular death Fatal cerebrovascular events Fatal cardiovascular events Fatal peripheral vascular events All causes of death Amputation Development of critical limb ischemia